Report Details

Alzheimer's medicine - your guide to technologies, trends and revenues

Where's treatment of Alzheimer's disease heading? Visiongain's new report gives you revenue predictions for those drugs and diagnostic tests from 2013, helping you stay ahead.

There you find financial data, R&D trends, opportunities, and prospects. In particular, you see forecasted sales to 2023 at overall world market, submarket, product, and national level.

Read on, then, to explore that industry and see what its future market could be worth.

Forecasts to 2023 and other analyses to help you stay ahead

Besides revenue forecasting to 2023, you find historical data, growth rates, and market shares. You assess quantitative and qualitative analysis, business news, outlooks, and developments (R&D). You also gain 40 tables, 63 charts, and an interview.

Many opportunities exist for diagnosis and treatment of Alzheimer's. Our study shows you the most promising and lucrative parts of that CNS market, helping you stay ahead. Now see how you can benefit your research, analyses and decisions, also saving time.

Finding data you need on that neurodegenerative disorder has just got easier. The following sections show how you benefit from our new analysis.

Discover outlooks for the world market and submarkets

Along with prediction of overall world market value to 2023, our report shows you revenue forecasting for main submarkets at world level:
• Medicines for Alzheimer's disease
• Diagnostics for Alzheimer's (including biomarkers).

Also our study discusses what stimulates and restrains that market. That analysis helps you identify potential and find ways for your business to develop. Assess brands too.

See forecasts for Alzheimer's drugs

How will drugs perform to 2023 at world level? Our study predicts individual revenues of three products:
• Namenda
• Aricept
• Exelon.

There you discover how high sales can go, to 2023. You see what's happening, then, understanding trends, competition, challenges, and opportunities.

You find geographical revenue predictions too.

Discover prospects of national markets for those anti-dementia products

Developments worldwide expand the market for diagnosing, treating and monitoring neurodegenerative disorders. Developed and developing national markets hold high potential from 2013.

Our analyses show you individual revenue forecasts to 2023 for nine national markets and a regional block:
• US
• Japan
• Germany, France, UK, Italy, and Spain (EU5)
• Europe (grouped forecast)
• India and China.

There you find potential. Large companies and specialty biopharma and diagnostics firms face many opportunities. Our study explains, assessing developments to help your work.

What affects producers of those diagnostic tests and medicines?

Our report discusses issues and events affecting that industry and market from 2013, including these:
• Research and development (R&D) - drugs, diagnostic tests, and related technologies
• Disease prevalence - expanding patient populations
• Disease-modifying drugs and obstacles to cures
• Regulatory guidelines - changes and opportunities.

The study also discusses other aspects of diagnosing and treating Alzheimer's:
• Needs for Alzheimer's treatments
• Drugs and related technologies to transform the market
• Biomarkers and diagnostic imaging technologies, including structural, functional, and molecular imaging
• Deep brain stimulation (functional neuromodulation)
• Intellectual property (IP), licensing agreements and partnerships.

That way, you explore the industry's strengths, weaknesses, opportunities, and threats. You also analyse it through Porter's five forces.

See, then, what the future holds.

Prominent companies in that biomedical field and 2017 market value

Our new study predicts the world market for Alzheimer's products will reach $8.3bn in 2017, and expand fast - especially from 2018.

Disease-modifying therapies will transform that market. New drugs hold great potential from 2018 to 2023, given the prevalence of Alzheimer's and needs for more-effective treatments.

Our work thus shows you what technologies, products, and organisations hold greatest potential. In particular, the analysis investigates these companies:
• Pfizer
• Eisai
• Forest Laboratories
• Lundbeck
• Novartis
• TauRx Therapeutics
• AC Immune.

There you assess results, product ranges, R&D pipelines, and outlooks.

Prospects for Alzheimer's products and R&D are strong, and from 2013 there will arise many opportunities. Our work shows you the possibilities there, helping you stay ahead.

Eight ways Alzheimer's Disease Therapeutics and Diagnostics: World Market 2013-2023 helps you

In particular, then, our investigation gives you the following knowledge:
• Revenue to 2023 for the world market - discover that industry's overall sales potential
• Revenues to 2023 for world-level submarkets - investigate the potential of its components, finding the most promising places for investments and revenues
• Revenues to 2023 for top products - find sales outlooks for top brands, seeing how they can compete and succeed
• Forecasts to 2023 for national markets in North America, Europe, and Asia - discover the best countries for revenues and potential growth
• Assessments of prominent companies - hear about developers and manufacturers' activities, results, and outlooks
• Review of R&D - explore progress in research and development, finding technological and medical possibilities for that neurological disorder
• Competition and opportunities - investigate what shapes that market's future, including ways to develop business
• Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and get advantages.

You gain information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Assess progress and potential now, seeing what you can gain.

Discover predictions for Alzheimer's-related products by ordering now

Our study lets you find data, trends, opportunities, and sales predictions for Alzheimer's medicine. Avoid missing out - please order our new report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Table Of Contents

Table of Contents

1. Executive Summary
1.1 Overview of Findings
1.2 Structure of the Report
1.3 Research and Analysis Methods

2. Alzheimer's Disease: An Introduction
2.1 Neurodegenerative Diseases
2.1.1 What is Alzheimer's Disease?
2.1.2 What Causes Alzheimer's Disease?
2.1.2.1 Alzheimer's Disease: Type 3 Diabetes?
2.1.3 Management of Alzheimer's Disease
2.1.4 The Socio-Economic Impact of Alzheimer's Disease
2.1.5 Diagnosis of Alzheimer's Disease

3. Alzheimer's Disease Therapeutics and Diagnostics Market, 2013-2023
3.1 Alzheimer's Disease Therapeutics and Diagnostics Market, 2012
3.2 Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2012-2017
3.2.1 The Market Has Been Left Exposed to Intensified Generic Competition
3.3 Alzheimer's Disease Therapeutics and Diagnostics Market Forecast, 2017-2023
3.3.1 Healthcare Costs for Alzheimer's Disease Will Surpass All Other Medical Expenses
3.3.2 The Current Drugs and Diagnostics Pipeline Is Strong
3.3.3 New Diagnostics and Drugs Regulatory Guidelines Will Lower the Barriers to Entry
3.4 Drivers and Restraints

4. The Alzheimer's Disease Drugs Market, 2013-2023
4.1 Current Approaches and Unmet Needs in the Treatment of Alzheimer's Disease
4.2 The Alzheimer's Disease Drugs Market, 2012
4.3 The Alzheimer's Disease Drugs Market Forecast, 2012-2017
4.4 The Alzheimer's Disease Drugs Market Forecast, 2017-2023
4.4.1 Novel Drugs Will Dramatically Alter the AD Drugs Market to 2023
4.4.2 A Global Aging Population Will Increase Disease Prevalence Over the Forecast Period
4.5 Namenda
4.5.1 Namenda Sales Forecast 2013-2023
4.6 Aricept
4.6.1 Aricept Sales Forecast, 2013-2023
4.7 Exelon
4.7.1 Exelon Sales Forecast, 2013-2023
4.8 Alzheimer's Disease Drugs Pipeline, 2013
4.8.1 Recent High-Profile Failures of Drugs in Development
4.8.1.1 Gammagard
4.8.1.2 Bapineuzumab
4.8.1.3 Solanezumab
4.8.1.4 Dimebon
4.8.1.5 Avagacestat
4.8.2 FDA to Relax Rules for the Approval of Alzheimer's Drugs
4.8.3 Will Novel Drug Development Strategies Prove Successful?
4.8.4 Promising Therapies in the Alzheimer's Disease Pipeline, 2013
4.8.4.1 Gantenerumab (Roche)
4.8.4.2 TTP488 (TransTech Pharma)
4.8.4.3 SB-742457 (GlaxoSmithKline)
4.8.4.4 CERE-110 (Ceregene)
4.8.4.5 LMTX, TRx0237 (TauRx)
4.8.4.6 EVP-6124 (EnVivo Pharmaceuticals)
4.8.4.7 AD02 (Affiris)
4.8.4.8 Deep Brain Stimulation (Functional Neuromodulation)
4.9 Leading Companies in the Alzheimer's Disease Drugs Market, 2012
4.9.1 Pfizer, Inc.
4.9.1.1 Sales and Recent Performance Analysis, 2012
4.9.1.2 Pfizer: Aricept
4.9.1.3 Pfizer: RandD Capabilities and Alzheimer's Disease Drug Candidates
4.9.1.4 Recent Discontinued Alzheimer's Disease Projects
4.9.2 Eisai Co., Ltd
4.9.2.1 Sales and Recent Performance Analysis, 2012
4.9.2.2 Eisai: Aricept
4.9.2.3 Alzheimer's Disease Drug Pipeline
4.9.2.4 Partnership with GE Healthcare for Diagnostic Development
4.9.3 Forest Laboratories
4.9.3.1 Sales and Recent Performance Analysis, 2012
4.9.3.2 Forest: Namenda
4.9.4 Lundbeck A/S
4.9.4.1 Sales and Recent Performance Analysis, 2012
4.9.4.2 Ebixa
4.9.4.3 Alzheimer's Disease Drug Pipeline
4.9.5 Novartis AG
4.9.5.1 Sales and Recent Performance Analysis, 2012
4.9.5.2 Novartis: Exelon
4.9.5.3 eHealth Programme: Delivering Innovation
4.9.5.4 Alzheimer's Disease Drug Pipeline
4.9.6 TauRx
4.9.6.1 Partnership with Bayer Schering Pharma AG
4.9.7 AC Immune
4.9.7.1 Groundbreaking $100m Trial for Alzheimer's Therapy
4.9.7.2 AC Immune Halts Development of AC-91

5. The Alzheimer's Disease Diagnostics Market, 2013-2023
5.1 There is Still a Strong Market Need for Effective Diagnosis
5.2 The Alzheimer's Disease Diagnostics Market, 2012
5.3 New Criteria and Guidelines to Diagnose Alzheimer's Disease
5.4 Biomarkers for Alzheimer's Disease
5.4.1 Leading Companies Pursuing Novel Biomarker Development Strategies
5.5 Alzheimer's Disease: Advances in Diagnostic Imaging Technologies
5.5.1 Structural Imaging
5.5.2 Functional Imaging
5.5.3 Molecular Imaging Technologies
5.5.3.1 Pittsburgh Compound B (PIB)
5.5.3.2 18F Flutemetamol
5.5.3.3 Florbetapir F18 (18F-AV-45)
5.5.3.4 Florbetaben (Bay 94-9172)
5.5.3.5 Other Alzheimer's Radiotracers in Development
5.6 Alzheimer's Disease Diagnostics Market Forecast, 2012-2017
5.7 Alzheimer's Disease Diagnostics Market Forecast, 2017-2022
5.8 Leading Companies in The Alzheimer's Disease Diagnostics Market, 2013
5.8.1 Eli Lilly
5.8.1.1Recent Performance and Sales Analysis, 2012
5.8.1.2 Alzheimer's Disease Research Efforts
5.8.1.2.1 Solanezumab
5.8.1.2.2 Amyvid
5.8.1.2.3 Amyvid Receives Marketing Authorization from the European Commission
5.8.1.2.4 Eli Lilly Acquires Novel Tau Tangle Diagnostic Programme
5.8.2 DiaGenic
5.8.2.1 Collaborative Agreement with Pfizer
5.8.3 Amarantus BioScience Holdings, Inc.
5.8.3.1 LymPro
5.8.3.2 Intellectual Property Acquisitions
5.8.4 Piramal Enterprises
5.8.4.1 Piramal Imaging SA
5.8.4.2 Regulatory Acceptance for Review of Florbetaben
5.8.4.3 Manufacturing and Distribution Agreements
5.8.5 GE Healthcare
5.8.5.1 GE's Commitment to Imaging Research in the Alzheimer's Field
5.8.5.2 Regulatory Acceptance for Review of Flutemetamol
5.8.5.3 Licensing Agreements for Flutemetamol

6. The Leading National Markets, 2013-2023
6.1 Regional Breakdown of the Global Alzheimer's Disease Therapeutics and Diagnostics Market, 2012
6.1.1 The US and Europe Represent More Than 70% of the Total Market
6.2 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Regional Forecast, 2013-2023
6.3 Changing Market Shares of Leading National Markets, 2013-2023
6.4 The US Alzheimer's Disease Therapeutics and Diagnostics Market, 2012-2023
6.4.1 One in Eight Over the Age of 65 has AD in the US
6.4.2 The US Will Remain the Largest Market Over the Forecast Period
6.5 The European Alzheimer's Disease Therapeutics and Diagnostics Market, 2012-2023
6.5.1 Germany 2012-2023: The Largest European Market
6.5.2 The French Market, 2012-2023: Highest Healthcare Spender in Europe
6.5.3 The UK Market, 2012-2023: Spending Restrictions
6.5.4 The Spanish Market, 2012-2023: Cost Containment Measures Will Continue to Affect the Market
6.5.5 The Italian Market, 2012-2023
6.6 The Japanese Market, 2012-2023: The Second Largest National Market in 2012
6.7 The Chinese Market, 2012-2023: One of the Fastest Growing Markets
6.8 The Indian Market, 2012-2023: Improvements in Regulations Will Boost the Market to 2023

7. Qualitative Analysis of the Alzheimer's Disease Therapeutics and Diagnostics Market, 2013
7.1 SWOT Analysis
7.2 Strengths
7.2.1 Alzheimer's Disease is a High Profile Disease
7.2.2 Expanding Patient Population
7.2.3 Strong RandD Pipeline in Both Sectors of the Market
7.3 Weaknesses
7.3.1 Current Drugs Only Treat the Symptoms of Alzheimer's Disease
7.3.2 Recent Failures of Promising Drug Candidates in Clinical Trials
7.3.3 Poor Macroeconomic Conditions in Key Regions of the Market
7.4 Opportunities
7.4.1 Regulators Seeking Improved Standards of Alzheimer's Disease Drug Development
7.4.2 Neurodegenerative Diseases Have Strong RandD
7.4.3 Emerging Markets Will Help Drive the Market
7.4.4 Advances in Diagnostic Technologies Will Improve Drug Market Penetration
7.5 Threats
7.5.1 Patent Expiries Will Lead to Further Generic Competition
7.5.2 New AD Therapies Face Political, Commercial and Social Pressures
7.6 Porter's Five Force Analysis
7.6.1 Rivalry Among Competitors
7.6.2 Threat of New Entrants
7.6.3 Power of Suppliers
7.6.4 Bargaining Power of Suppliers
7.6.5 Threat of Substitutes

8. Research Interview
8.1 Interview with Professor Jürgen Götz
8.1.1 The Obstacles for Developing a Cure for Alzheimer's Disease
8.1.2 The Time Frame for Developing a Cure for Alzheimer's Disease
8.1.3 Potential Alzheimer's Disease Treatments
8.1.4 The Market Potential for a Cure for Alzheimer's Disease

9. Conclusions
9.1 Disease-Modifying Drugs and Novel Diagnostic Technologies Will Transform the Market
9.2 Demographics Will Help Drive the Market Over the Forecast Period
9.3 Medicines and Diagnostic Tests for Alzheimer's Disease Hold Great Potential from 2013 to 2023



List of Tables

Table 2.1 Leading Sectors in the Neurodegenerative Disease Market, 2013
Table 2.2 Imaging Technologies Used in Alzheimer's Research, 2013
Table 3.1 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) and Market Shares (%) by Sector, 2012
Table 3.2 Alzheimer's Disease Therapeutics and Diagnostics Market Forecasts: Revenues ($bn), AGR (%), CAGR (%), 2012-2017
Table 3.3 Alzheimer's Disease Therapeutics and Diagnostics Market Forecasts: Revenues ($bn), AGR (%), CAGR (%), 2017-2023
Table 3.4 The Alzheimer's Disease Therapeutics and Diagnostics Market: Drivers and Restraints, 2013
Table 4.1 The Alzheimer's Disease Drugs Market: Revenues ($bn) and Market Shares (%) by Leading Drugs, 2012
Table 4.2 Alzheimer's Disease Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2017
Table 4.3 Alzheimer's Disease Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2017-2023
Table 4.4 Selected List of Alzheimer's Disease Drugs in the Pipeline, 2013
Table 4.5 Pfizer: Revenues ($bn) and Revenue Shares (%) by Sector, 2012
Table 4.6 Pfizer: Aricept Revenue Forecast ($bn), AGR (%), CAGR (%), 2012-2023
Table 4.7 Pfizer: Alzheimer's Disease Drug Pipeline, 2013
Table 4.8 Eisai: Aricept Revenue Forecast ($bn), AGR (%), CAGR (%), 2012-2023
Table 4.9 Forest: Namenda's Historical Revenues ($bn), AGR (%) and Percentage of Net Sales (%), 2009-2013
Table 4.10 Forest: Namenda Sales Forecast ($bn), AGR (%), CAGR (%), 2012-2023
Table 4.11 Lundbeck: Revenues ($bn) and Revenue Shares (%) by Region, 2012
Table 4.12 Ebixa: Revenues ($bn) and Revenue Shares (%) by Region, 2012
Table 4.13 Ebixa: Sales Forecast ($bn), AGR (%), CAGR (%), 2012-2023
Table 4.14 Novartis: Revenue ($bn) and Revenue Shares (%) by Segment, 2012
Table 5.1 The Alzheimer's Disease Diagnostics Market: Revenues ($bn) and Market Shares (%) by Segment, 2012
Table 5.2 The Alzheimer's Disease Diagnostics Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Sector, 2012-2017
Table 5.3 The Alzheimer's Disease Diagnostics Market Forecast: Revenues ($bn), AGR (%), CAGR (%), by Sector, 2017-2023
Table 5.4 Diagenic: Diagnostics Pipeline, 2013
Table 6.1 The Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) and Market Shares (%) by Region, 2012
Table 6.2 The Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), AGR (%), CAGR (%), by Region, 2012-2017
Table 6.3 The Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), AGR (%), CAGR (%), by Region, 2017-2023
Table 6.4 Regional Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2012-2017, 2017-2023 and 2012-2023
Table 6.5 Market Shares (%) of the Leading Regional Alzheimer's Disease Therapeutics and Diagnostics Markets, 2012, 2017 and 2023
Table 6.6 The US Alzheimer's Disease Therapeutics and Diagnostics Market Forecast Summary: Size ($bn), Rank, Share (%), CAGR (%), 2012-2023
Table 6.7 The European Alzheimer's Therapeutics and Diagnostics Market: Revenues ($bn), European Market Share (%) and Global Market Share (%) by Leading Countries, 2012
Table 6.8 The European Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Leading Country, 2012-2017
Table 6.9 The European Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Leading Country, 2017-2023
Table 6.10 The Japanese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast Summary: Size ($bn), Rank, Share (%), CAGR (%), 2012-2023
Table 6.11 The Chinese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast Summary: Size ($bn), Rank, Share (%), CAGR (%), 2012-2023
Table 6.12 The Indian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast Summary: Size ($bn), Rank, Share (%), CAGR (%), 2012-2023
Table 6.13 India: Population Forecast by Age Group (%), 2010, 2015 and 2020
Table 7.1 SWOT Analysis of the Alzheimer's Disease Therapeutics and Diagnostics Market, 2013
Table 9.1 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) by Region, in 2012, 2017 and 2023
Table 9.2 The Global Alzheimer's Disease Therapeutics and Diagnostics Market ($bn) by Sector, 2012, 2017 and 2023



List of Figures

Figure 3.1 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) by Sector, 2012
Figure 3.2 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Market Shares (%) by Sector, 2012
Figure 3.3 The Global Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), 2012-2017
Figure 3.4 The Global Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), 2017-2023
Figure 4.1 The Alzheimer's Disease Drugs Market: Revenues ($bn) by Leading Drugs, 2012
Figure 4.2 The Alzheimer's Disease Drugs Market: Market Shares (%) by Leading Drugs, 2012
Figure 4.3 The Alzheimer's Disease Drugs Market Forecast: Revenues ($bn), 2012-2017
Figure 4.4 The Alzheimer's Disease Drugs Market Forecast: Revenues ($bn), 2017-2023
Figure 4.5 The Other Treatments Market Forecast: Revenues ($bn), 2012-2023
Figure 4.6 Namenda: Revenue Forecast ($bn), 2012-2023
Figure 4.7 Aricept: Sales Forecast ($bn), 2012-2023
Figure 4.8 Exelon: Sales Forecast ($bn), 2012-2023
Figure 4.9 Pfizer: Historical Revenues ($bn), Net Income ($bn) and Profit Margin (%), 2009-2012
Figure 4.10 Pfizer: Revenues ($bn) by Sector, 2012
Figure 4.11 Pfizer: Revenue Shares (%) by Sector, 2012
Figure 4.12 Pfizer: Aricept Historical Revenues ($bn) and Annual Growth Rates (%), 2008-2012
Figure 4.13 Pfizer: Aricept Revenue Forecast ($bn), 2012-2023
Figure 4.14 Pfizer: Historical RandD Expenditure ($bn) and RandD Expenditure as Percentage of Revenue (%), 2009-2012
Figure 4.15 Eisai: Aricept Revenue Forecast ($bn), 2012-2023
Figure 4.16 Forest Laboratories: Historical Revenues ($bn), Net Income/Loss ($bn) and Profit Margin (%), 2009-2013
Figure 4.17 Forest: Namenda's Historical Revenues ($bn) and AGRs (%), 2009-2013
Figure 4.18 Forest: Namenda's Quarterly Revenues ($bn), Fiscal Year 2013
Figure 4.19 Forest: Namenda Sales Forecast ($bn), 2012-2023
Figure 4.20 Lundbeck: Revenue Shares (%) by Region, 2012
Figure 4.21 Lundbeck: Revenues ($bn) by Region, 2012
Figure 4.22 Ebixa: Revenue Shares (%) by Region, 2012
Figure 4.23 Ebixa: Sales Forecast ($bn), 2012-2023
Figure 4.24 Novartis: Historical Revenues ($bn), Net Income ($bn) and Profit Margin (%), 2009-2012
Figure 4.25 Novartis: Revenues ($bn) by Segment, 2012
Figure 4.26 Novartis: Revenue Shares (%) by Segment, 2012
Figure 4.27 Exelon: Revenue Shares (%) by Region, 2012
Figure 5.1 The Alzheimer's Disease Diagnostics Market: Revenues ($bn) by Segment, 2012
Figure 5.2 The Alzheimer's Disease Diagnostics Market: Market Shares (%) by Segment, 2012
Figure 5.3 The Alzheimer's Disease Diagnostics Market Forecast: Revenues ($bn), 2012-2017
Figure 5.4 The Alzheimer's Disease Diagnostics Market Forecast: Revenues ($bn), 2017-2023
Figure 5.5 Eli Lilly: Historical Revenues ($bn), Net Income ($bn), Profit Margin (%), 2010-2012
Figure 6.1 The Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) by Region, 2012
Figure 6.2 The Alzheimer's Disease Therapeutics and Diagnostics Market: Market Shares (%) by Region, 2012
Figure 6.3 Regional Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2012-2017
Figure 6.4 Regional Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2017-2023
Figure 6.5 Regional Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2012-2023
Figure 6.6 The Alzheimer's Therapeutics and Diagnostics Market: Market Shares (% by Region, 2017
Figure 6.7 The Alzheimer's Therapeutics and Diagnostics Market: Market Shares (%) by Region, 2023
Figure 6.8 The US Alzheimer's Disease Therapeutics and Diagnostics Market Forecast ($bn), 2012-2023
Figure 6.9 US Demographics: No. of People Aged 65 or Over, 2012 and 2022
Figure 6.10 The European Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) by Leading Countries, 2012
Figure 6.11 The European Alzheimer's Disease Therapeutics and Diagnostics Market: Market Shares (%) by Leading Countries, 2012
Figure 6.12 The European Alzheimer's Disease Therapeutics and Diagnostics Market Forecast ($bn), 2012-2023
Figure 6.13 The European Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: CAGR (%) by Leading Countries, 2012-2023
Figure 6.14 The German Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), 2012-2023
Figure 6.15 The French Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), 2012-2023
Figure 6.16 The UK Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), 2012-2023
Figure 6.17 The Spanish Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), 2012-2023
Figure 6.18 The Italian Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), 2012-2023
Figure 6.19 The Japanese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), 2012-2023
Figure 6.20 The Chinese Alzheimer's Disease Therapeutics and Diagnostics Market Forecast: Revenues ($bn), 2012-2023
Figure 6.21 China's Historical Healthcare Expenditure ($bn), 2001-2010
Figure 6.22 The Indian Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn), 2012-2023
Figure 7.1 Proportion of Population (%) Aged 60 or Over: World, 1950, 2009 and 2050
Figure 7.2 Porter's Five Force Analysis of the Alzheimer's Disease Therapeutics and Diagnostics Market, 2013
Figure 9.1 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) in 2012, 2017 and 2023
Figure 9.2 The Global Alzheimer's Disease Therapeutics and Diagnostics Market: Revenues ($bn) by Leading Countries in 2012, 2017 and 2023
Figure 9.3 The Global Alzheimer's Disease Therapeutics and Diagnostics Market ($bn) by Segment in 2012, 2017 and 2023



Companies Listed

Abbott Laboratories
AC Immune
Adamas Pharmaceuticals
Affiris
Alzheimer's Association
Amarantus Bioscience Holdings American Academy of Neurology
AstraZeneca
Avid Radiopharmaceuticals
Baxter International
Bayer
BioArctic Neuroscience
Bristol-Myers Squibb
Ceregene
Cytos
DiaGenic
Eisai
Elan
Eli Lilly
EnVivo Pharmaceuticals
European Medicines Agency (EMA)
Forest Laboratories
Food and Drug Administration (US FDA)
French Economic Committee
Functional Neuromodulation
GE Healthcare
GlaxoSmithKline (GSK)
Healthcare Ministry (China)
IBA Molecular
Janssen Pharmaceuticals
Johnson and Johnson (JandJ)
Lundbeck
Medivation
MemoryDx
Merck and Co.
Merz
Mount Sinai School of Medicine
Nanotherapeutics
National Institute of Aging
Novartis
Otsuka Pharmaceutical
Pfizer
Piramal Enterprises
Piramal Imaging
Power3 Medical Products
Proterra
QR Pharma
Raptor Pharmaceuticals
Roche
Sanko Junyaku
Sanofi
Shire
Siemens Medical Solutions
Sonexa Therapeutics
TauRx Pharmaceuticals
Toyama Chemical Co.
Transition Therapeutics
TransTech Pharma
United Nations (UN)
University of California, Los Angeles (UCLA)
Wyeth (now part of Pfizer)

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

  • $ 9 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022 Summary Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, ...

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 9 995
  • Industry report
  • April 2014
  • by Global Data

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most ...

Neurostimulation: Technologies and Global Markets

Neurostimulation: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • March 2014
  • by BCC Research

REPORT HIGHLIGHTS The global neurostimulation devices market is expected to reach $3.8 billion in 2013 and $4.1 billion in 2018, with a compound annual growth rate (CAGR) of 1.5%. This report provides: ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.